SurModics Inc (SRDX) - Total Assets
Based on the latest financial reports, SurModics Inc (SRDX) holds total assets worth $169.82 Million USD as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore SRDX operating cash to total liabilities to assess how comfortably operating cash covers total debt obligations.
SurModics Inc - Total Assets Trend (1998–2024)
This chart illustrates how SurModics Inc's total assets have evolved over time, based on quarterly financial data. See SurModics Inc shareholders equity for net asset value and shareholders' equity analysis.
SurModics Inc - Asset Composition Analysis
Current Asset Composition (September 2024)
SurModics Inc's total assets of $169.82 Million consist of 45.5% current assets and 54.5% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 20.2% |
| Accounts Receivable | $23.27 Million | 13.0% |
| Inventory | $15.17 Million | 8.5% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $23.57 Million | 13.2% |
| Goodwill | $44.64 Million | 25.0% |
Asset Composition Trend (1998–2024)
This chart illustrates how SurModics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see SurModics Inc stock valuation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: SurModics Inc's current assets represent 45.5% of total assets in 2024, an increase from 27.2% in 1998.
- Cash Position: Cash and equivalents constituted 20.2% of total assets in 2024, up from 5.4% in 1998.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 38.0% of total assets, an increase from 0.0% in 1998.
- Asset Diversification: The largest asset category is goodwill at 25.0% of total assets.
SurModics Inc Competitors by Total Assets
Key competitors of SurModics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Bio-Rad Laboratories Inc
NYSE:BIO
|
USA | $9.79 Billion |
|
Double Medical Technology Inc
SHE:002901
|
China | CN¥5.03 Billion |
|
Tellgen Corp
SHE:300642
|
China | CN¥2.01 Billion |
|
Affluent Medical SAS
PA:AFME
|
France | €59.84 Million |
|
Cochlear Ltd
AU:COH
|
Australia | AU$2.83 Billion |
|
4DMEDICAL Ltd
AU:4DX
|
Australia | AU$139.55 Million |
|
Anteris Technologies Global Corp
AU:AVR
|
Australia | AU$19.07 Million |
|
Imricor Medical Systems Inc
AU:IMR
|
Australia | AU$45.79 Million |
SurModics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.91 | 3.98 | 4.58 |
| Quick Ratio | 3.10 | 3.22 | 4.27 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $56.55 Million | $60.16 Million | $67.72 Million |
SurModics Inc - Advanced Valuation Insights
This section examines the relationship between SurModics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.52 |
| Latest Market Cap to Assets Ratio | 3.44 |
| Asset Growth Rate (YoY) | -3.9% |
| Total Assets | $178.56 Million |
| Market Capitalization | $614.51 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values SurModics Inc's assets at a significant premium (3.44x), suggesting investors see substantial growth potential or unique competitive advantages.
Slight Asset Contraction: SurModics Inc's assets decreased by 3.9% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for SurModics Inc (1998–2024)
The table below shows the annual total assets of SurModics Inc from 1998 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-09-30 | $178.56 Million | -3.86% |
| 2023-09-30 | $185.73 Million | +17.29% |
| 2022-09-30 | $158.36 Million | -18.62% |
| 2021-09-30 | $194.59 Million | +15.30% |
| 2020-09-30 | $168.76 Million | +5.57% |
| 2019-09-30 | $159.87 Million | -2.60% |
| 2018-09-30 | $164.13 Million | +20.16% |
| 2017-09-30 | $136.59 Million | +2.78% |
| 2016-09-30 | $132.89 Million | +32.62% |
| 2015-09-30 | $100.21 Million | -4.46% |
| 2014-09-30 | $104.89 Million | +2.91% |
| 2013-09-30 | $101.92 Million | -1.87% |
| 2012-09-30 | $103.87 Million | -36.14% |
| 2011-09-30 | $162.65 Million | -4.48% |
| 2010-09-30 | $170.28 Million | -8.24% |
| 2009-09-30 | $185.56 Million | -2.86% |
| 2008-09-30 | $191.03 Million | +11.50% |
| 2007-09-30 | $171.33 Million | +8.85% |
| 2006-09-30 | $157.40 Million | +26.71% |
| 2005-09-30 | $124.22 Million | +13.16% |
| 2004-09-30 | $109.78 Million | +12.24% |
| 2003-09-30 | $97.81 Million | +26.62% |
| 2002-09-30 | $77.25 Million | +27.51% |
| 2001-09-30 | $60.58 Million | +19.38% |
| 2000-09-30 | $50.75 Million | +58.59% |
| 1999-09-30 | $32.00 Million | +31.69% |
| 1998-09-30 | $24.30 Million | -- |
About SurModics Inc
Surmodics, Inc., together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment engages in the provision o… Read more